Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Phase 4

Completed

• Conditions: Dyslipidemia; Hypertension

• Registration Number: NCT00350038
• Lead Sponsor: Sanofi

Brief Summary

The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-02
• Study First Submitted: 2006-07-07
• Study First Submitted QC: 2006-07-07
• Study First Posted: 2006-07-10
• Study Completion: 2007-08
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-18
• Last Update Posted: 2008-01-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• hypertensive + dyslipidemic + damaged endothelial function

Exclusion Criteria

• hepatic and kidney damage,
• IDDM (Insulin Dependent Diabetes Mellitus)
• Freckson V type hyperlipoproteinaemia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Microvascular reactivity

Secondary Outcome Measures

Name	Time	Method
Reach of target blood pressure
Measurements of safety laboratory parameters

Trial Locations

Locations (1)

Sanofi-aventis; 🇭🇺 Budapest, Hungary